Non‐coding RNA LOXL1-AS1 exhibits oncogenic activity in ovarian cancer via regulation of miR‐18b‐5p/VMA21 axis

Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Fang Xue, Yan Hua Xu, Cheng Cheng Shen, Zhen Li Qin, Hai Bin ZhouAbstractLong non-coding RNAs (lncRNAs) exert critical effects in the process of malignant cancers and lncRNA LOXL1 Antisense RNA 1 (LOXL1-AS1) has been demonstrated to be a pro-oncogene in multiple tumor types. In the current study, we illuminated the precise roles of LOXL1-AS1 in the development of ovarian cancer. LOXL1-AS1 is significantly overexpressed in ovarian carcinoma tissue compared with adjacent non‐cancerous sample. The luciferase reporter gene assay reveals the relationship between LOXL1-AS1 and miR‐18b‐5p, miR‐18b‐5p and its target gene, Vacuolar ATPase Assembly Factor VMA21 (VMA21). Transfection of LOXL1-AS1 siRNA or miR‐18b‐5p mimics inhibits the growth and aggressive phenotypes of SKOV3 and OVCAR3 cell. Furthermore, miR-18b-5p suppresses ovarian carcinoma cell proliferation and metastasis by targeting VMA21 and LOXL1-AS1 regulates ovarian carcinoma cell growth and metastasis through sponging miR‐18b‐5p. These findings suggest that lncRNA LOXL1-AS1 promotes ovarian cancer cell growth, migratory and invasiveness via modulating miR‐18b‐5p/VMA21 axis.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research